MedImmune to cut 200 jobs, layoffs hit vax R&D

MedImmune will ax 200 employees and close its California sites in Mountain View and Santa Clara in a consolidation of its infectious disease and vaccines R&D and operations.

Another 100 employees who make it through the cuts will move to other MedImmune locations such as its in Hayward, CA, site. The company plans to invest in the site, adding more capabilities to the facilities. It will wrap up the restructuring in 2014.

The company's release, while vague on the details, does say the layoffs and reorganization come as part of the plan of its parent company, AstraZeneca ($AZN), to improve productivity and streamline processes. AstraZeneca will shed 7,300 jobs this year.

MedImmune says that the cuts won't impact delivery of its vaccines, which include the FluMist intranasal flu vaccines.

- read the release

Related Articles:
AstraZeneca cutting 2,200 R&D jobs, slashing neuroscience in restructuring
New chairman ramps up CEO search at struggling AZ
Brennan's ouster at AstraZeneca sets stage for big changes in R&D

Like what you're reading?
Click here to get more news delivered to your inbox every week>>
 

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.